Correlation of Clinical Effects with Levels of Fetuin-A, FGF-23 and intact Parathormone in Peritoneal Dialysis Patients

Objective: We aimed to demonstrate the clinical effects of fetuin–A, fibroblast growth factor-23 and intact parathormone on the risk factors for metabolic disorders and cardiovascular diseases in peritoneal dialysis patients. Materials and Method: A total of 41 patients who had undergone peritoneal dialysis therapy were included in the study. The study groups were divided into two groups according to intact parathormone levels, which were below and above 72 pg/mL. Serum levels of fetuin-A, fibroblast growth factor-23, biochemical parameters and carotid intima media thickness were measured in both the groups. Echocardiography was performed. Result: Mean fetuin-A levels were not found to be lower and no statistically significant difference was determined between the two groups. No correlations were demonstrated between the levels of fetuin-A and the risk factors for cardiovascular diseases and biochemical parameters. Mean fibroblast growth factor-23 levels were significantly higher. No statistically significant difference was observed in the levels of fibroblast growth factor-23 between the groups. No correlations were determined between the levels of fibroblast growth factor-23 and the risk factors for cardiovascular diseases and biochemical parameters, except LDL-cholesterol. A significant negative correlation was found between the levels of fibroblast growth factor-23 and LDL-cholesterol. Conclusion: No unfavorable effects of serum fetuin-A and fibroblast growth factor-23 levels on cardiovascular morbidity were found. Dialysis adequacy, duration of dialysis, the use of  treatment and different mechanisms may be the cause of changes in clinical effects and levels of fetuin-A and fibroblast growth factor-23 in dialysis patients.